BRISTOL-MYERS SQUIBB CO (BMY)

US1101221083 - Common Stock

57.58  +0.25 (+0.44%)

After market: 57.58 0 (0%)

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (12/23/2024, 8:04:00 PM)

After market: 57.58 0 (0%)

57.58

+0.25 (+0.44%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-10%
Sales Q2Q%8.44%
CRS77.22
6 Month38.65%
Overview
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-06 2025-02-06/amc
Ins Owners0.07%
Inst Owners78.19%
Market Cap116.78B
Shares2.03B
PE49.21
Fwd PE8.09
Dividend Yield4.4%
Analysts68.13
Short Float %1.26%
Short Ratio2.51
IPO07-05 1929-07-05
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BMY Daily chart

Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Company Info

BRISTOL-MYERS SQUIBB CO

Route 206 And Province Line Road

Princeton NEW JERSEY 10016

P: 16092524621

CEO: Giovanni Caforio

Employees: 34100

Website: https://www.bms.com/

BMY News

News Image21 hours ago - Bristol Myers SquibbBristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
News Image21 hours ago - Bristol Myers SquibbBristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
News Image22 hours ago - The Motley FoolGot $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
News Image3 days ago - The Motley FoolWant Decades of Passive Income? 3 Stocks to Buy Right Now

Passive income requires solid companies and a solid underlying industry. Here are some top names that fit both bills.

News Image5 days ago - Investor's Business DailyBristol Myers Squibb Stock Earns 83 RS Rating

On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.

News Image5 days ago - The Motley Fool3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income

BMY Twits

Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example